10x Genomics is trading at $63.03, down 10.09%, with no clear company-specific catalyst identified for the November 2 decline.
- Biotechnology shares were down, potentially presenting a sector headwind; broader-market information is mixed, so the cause remains uncertain.
- 10x Genomics announced a new AI tool for single-cell analysis, but available reporting does not link its launch to the decline.
- Third-quarter results are scheduled after the close on November 5; the upcoming report is not an established cause.